P. Glorieux

Phase II study of dual phosphoinositol‐3‐kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

J. Machiels, B. Sautois, E. Seront, 2016, BJU international.

Denosumab mandibular adverse event in Nivolumab treated patient

R. Anghel, P. Glorieux, B. Pharmacy, 2020, Romanian Medical Journal.

Metastatic interstitial pneumonitis after autologous bone marrow transplantation: A consequence of reinjection of malignant cells?

P. Biron, P. Glorieux, E. Bouffet, 1986, Cancer.

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity.

Peter Hantos, Thomas C. Chen, Thomas C Chen, 2015, Vaccine.

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

H. Wildiers, A. Awada, E. de Azambuja, 2019, Breast cancer research and treatment.

Acute neuroborreliosis presenting with severe hyponatremia: a case report

P. Glorieux, P. Decleire, I. Ould-Nana, 2021, Journal of Community Hospital Internal Medicine Perspectives.

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

Thomas C Chen, V. Schijns, P. Glorieux, 2015, Vaccine.